Soterix Medical Inc. , the global leader in non-invasive stimulation and synergistic brain imaging technologies, has expanded clinical trials of its proprietary neuromodulation technologies for Alzheimer’s disease and Mild Cognitive Impairment.
Decline in cognitive skills is a part of advanced age and is related to loss of freedom and dementia risk. More than 50 million adults worldwide are diagnosed with Alzheimer’s disease or other dementia, which places a huge burden on people, their families and caretakers, and the health care system. Soterix Medical technology are in the forefront of Diagnosis of non-invasive therapies not simply to both treat diagnosed with Alzheimer’s disease and Moderate Cognitive Impairment but additionally stabilize, and even reverse, depletes cognitive decline.
With $6.2 million of assistance from the National Institutes of Health (NIH) National Institute of Aging (NIA), the Albert Einstein College of Medicine, Montefiore Health System, along with also the MJHS Health System will Assess the effectiveness of tDCS to relieve symptoms of Alzheimer’s disease and Enhance brain functioning. This new trial will influence Soterix Medical’s unique at-home tDCS platform, the mini-CT stimulator and ElectraRx™ remote management program. The double-blind research will assess the effects of six months of at-home tDCS on enhancing cognitive functioning and chosen symptoms in 100 patients using mild-to-moderate Alzheimer’s disease.
Since 2016, the NIH NIA has given $5.7 million University of Florida Health and the University of Arizona, to examine the effectiveness of Soterix Medical’s tDCS system in hastening the process of age-associated memory reduction and possibly stop onset of dementia. The 360 participant Augmenting Cardiovascular Training in Older Adults (ACT Research ) is a Stage III definitive multi-site randomized clinical trial to establish the advantage of producing adjunctive tDCS with cognitive therapy from elderly adults to purify the trajectory of cerebral cognitive decline.
The Veteran’s Administration and NIH are encouraging two double-blind, randomized controlled trials in patients with moderate cognitive impairment (146 subjects) or Alzheimer’s disease (100 subjects) with Soterix Medical’s proprietary High-Definition tDCS, a type of tDCS that could focally target brain areas.
